PSTV
PLUS THERAPEUTICS, INC.
$5.41
-5.91%
$39.5M
No data for this timeframe.
Vol
Market Cap$39.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders3 funds
Inst. Value$1.2M
Inst. Activity2 buys / 0 sells
Reddit Sentiment63° Warm
SEC Reports5
Press Releases4
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001095981·Prev Close $5.75
Recent Activity
Jun 5, 2026
SEC
Plus Therapeutics filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration (File No. 333-296411) as an exh
S-3/A — Impact 3/10
Jun 4, 2026
other
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complemen
May 19, 2026
Press
Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded by former Palantir h
Impact 4/10
May 15, 2026
SEC
Plus Therapeutics reported Q1 2026 EPS of -$1.05, a 19.2% miss vs consensus of -$0.87, on revenue of $1.0M (grant + CNSi
PRESS-RELEASE — Impact 6/10
May 14, 2026
Insider
Clowes Howard sold 3,686 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
HEDRICK MARC H sold 23,834 shares
Chief Executive Officer @ $0.00 ($0.00)
May 14, 2026
Insider
Sims Andrew John Hugh MacIntyre sold 3,443 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 21, 2026
SEC
Plus Therapeutics (PSTV) announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per s
8-K — Impact 4/10
Price Targets
$38.00
+602.4% upside
Strong Buy
Current $5.41
Low $12.00
Median $37.50
High $65.00
4 analysts
$12.00
$65.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Mar 31, 2026 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 22, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.87 | $-0.93 — $-0.79 | -435% YoY | 3 |
| Next Q | $-0.85 | $-0.89 — $-0.80 | 15% YoY | 3 |
| Current FY | $-3.87 | $-4.78 — $-3.39 | -1234% YoY | 4 |
| Next FY | $-2.37 | $-2.69 — $-1.98 | 39% YoY | 4 |
Latest Reports
NEUTRAL
S-3/A
3/10
Plus Therapeutics filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration (File No. 333-296411) as an exh
Jun 5, 2026
NEUTRAL
Press
4/10
Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded by former Palantir h
May 19, 2026
BEARISH
PRESS-RELEASE
6/10
Plus Therapeutics reported Q1 2026 EPS of -$1.05, a 19.2% miss vs consensus of -$0.87, on revenue of $1.0M (grant + CNSi
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.2M | ADD |
| BANK OF AMERICA CORP | $648.00 | ADD |
| WELLS FARGO & COMPANY/MN | $27.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Clowes Howard | A | $0.00 |
| May 14, 2026 | HEDRICK MARC | A | $0.00 |
| May 14, 2026 | Sims Andrew | A | $0.00 |
| May 14, 2026 | HEDRICK MARC | A | $0.00 |
| May 14, 2026 | Clowes Howard | A | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
3 institutional holders with $1.2M total value (2,280,732 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, WELLS. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,279,414 | $1.2M | 99.9% | ADD +57.5% |
| 2 | BANK OF AMERICA CORP /DE/ | 1,265 | $648.00 | 0.1% | ADD +52.2% |
| 3 | WELLS FARGO & COMPANY/MN | 53 | $27.00 | 0.0% | NEAR_EXIT -85.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 1,446,827 | 2,279,414 | +57.5% | $1.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 831 | 1,265 | +52.2% | $648.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 32,541 | 1,446,827 | +4346.2% | $989.6K | 2025-Q3 |
| UBS Group AG | DOUBLED | 87,638 | 623,874 | +611.9% | $426.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 158 | 831 | +425.9% | $567.00 | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 357 | 53 | -85.2% | $36.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 33,437 | 87,638 | +162.1% | $30.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 50 | 158 | +216.0% | $55.00 | 2025-Q2 |
| UBS Group AG | NEW | — | 33,437 | — | $31.8K | 2025-Q1 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Clowes Howard | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | HEDRICK MARC H | Chief Executive Officer | A | 23,834 | $0.00 | $0.00 |
| May 14, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | A | 3,443 | $0.00 | $0.00 |
| May 14, 2026 | HEDRICK MARC H | Chief Executive Officer | A | 23,834 | $0.00 | $0.00 |
| May 14, 2026 | Clowes Howard | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | A | 3,443 | $0.00 | $0.00 |
| May 14, 2026 | ANDREWS RONALD ASBURY | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | ANDREWS RONALD ASBURY | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | Guse Kyle | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | Guse Kyle | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | Hawkins Richard J | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | Hawkins Richard J | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | van Es-Johansson An | Director | A | 3,686 | $0.00 | $0.00 |
| May 14, 2026 | van Es-Johansson An | Director | A | 3,686 | $0.00 | $0.00 |
| Apr 20, 2026 | Daniels Eric Joseph | Chief Development Officer | A | 20,000 | $0.00 | $0.00 |
| Apr 20, 2026 | Daniels Eric Joseph | Chief Development Officer | A | 20,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | M | 38,323 | $0.00 | $0.00 |
| Apr 1, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | M | 38,323 | $0.00 | $0.00 |
| Apr 1, 2026 | HEDRICK MARC H | Chief Executive Officer | M | 159,681 | $0.00 | $0.00 |
| Apr 1, 2026 | HEDRICK MARC H | Chief Executive Officer | M | 159,681 | $0.00 | $0.00 |
| Feb 25, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | A | 349,542 | $0.00 | $0.00 |
| Feb 25, 2026 | Sims Andrew John Hugh MacIntyre | Chief Financial Officer | A | 349,541 | $0.00 | $0.00 |
| Feb 25, 2026 | HEDRICK MARC H | Chief Executive Officer | A | 2,419,582 | $0.00 | $0.00 |
| Feb 25, 2026 | HEDRICK MARC H | Chief Executive Officer | A | 2,419,582 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
S-3/A
3/10
Plus Therapeutics filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration (File No. 3
Jun 5, 2026
BEARISH
PRESS-RELEASE
6/10
Plus Therapeutics reported Q1 2026 EPS of -$1.05, a 19.2% miss vs consensus of -$0.87, on revenue of
May 15, 2026
NEUTRAL
8-K
4/10
Plus Therapeutics (PSTV) announced it has regained compliance with Nasdaq's minimum bid price requir
Apr 21, 2026
NEUTRAL
8-K
4/10
Plus Therapeutics appointed Dr. Eric J. Daniels as Chief Development Officer effective April 20, 202
Apr 9, 2026
BULLISH
8-K
7/10
Plus Therapeutics announced that its drug REYOBIQ received Orphan Drug Designation (ODD) from the FD
Apr 8, 2026
NEUTRAL
4/10
Plus Therapeutics announced a strategic partnership with Ephemeral Technologies, an AI firm founded
May 19, 2026
BULLISH
6/10
Plus Therapeutics presented a plenary session at the 2026 AANS Annual Meeting highlighting Phase 1 R
May 8, 2026
NEUTRAL
3/10
Plus Therapeutics subsidiary CNSide Diagnostics secured a new payer coverage agreement with Blue Shi
Apr 28, 2026
BULLISH
6/10
Plus Therapeutics announced a payer coverage agreement with Highmark, effective April 1, 2026, for i
Apr 2, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$38.00 mean target
+602.4% upside
Strong Buy (1.25)
$12.00 Low
$65.00 High
| Metric | Value |
|---|---|
| Current Price | $5.41 |
| Target Low | $12.00 |
| Target Mean | $38.00 |
| Target Median | $37.50 |
| Target High | $65.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.87 | $-0.93 | $-0.79 | -435.4% | — | 1↑ 1↓ | $0.0B | -20.1% | 3 |
| Next Q 2026-09-30 |
$-0.85 | $-0.89 | $-0.80 | 15.0% | — | 1↑ 1↓ | $0.0B | 4.9% | 3 |
| Current FY 2026-12-31 |
$-3.87 | $-4.78 | $-3.39 | -1234.5% | — | 1↑ 1↓ | $0.0B | 35.4% | 4 |
| Next FY 2027-12-31 |
$-2.37 | $-2.69 | $-1.98 | 38.9% | — | 1↑ 1↓ | $0.0B | 171.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.870 | |
| 7d ago | $-0.880 | +0.010 |
| 30d ago | $0.000 | -0.870 |
| 60d ago | $-0.813 | -0.057 |
| 90d ago | $-0.750 | -0.120 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 9, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 11, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
15 mentions
7 bullish
2 bearish
14 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 10, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 7, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 7, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 20, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
Recent Reddit Threads
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
▲ 2
💬 1
⚡ 0.5
PSTV : True Significance Additional Payer Contract Today
▲ 1
💬 1
⚡ 0.5
PSTV : A realistic 10-bagger from current levels.
▲ 1
💬 1
⚡ 0.5
PSTV Bright Future!
▲ 1
💬 1
⚡ 0.5
$PSTV ready for a 10x bagger
▲ 1
💬 1
⚡ 0.5
PSTV genuinely has ample potential for a 10x upside. (2)
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
other
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' existing CLIA certification
May 26, 2026
other
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
<p align="center"><em>Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making </em><br><em>reducing healthc
May 19, 2026
contract
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
<p align="center"><em>Partnership to deliver a novel AI-native integrated CNS oncology platform</em></p>
May 15, 2026
earnings
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
<p align="justify">HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company
May 8, 2026
fda
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
Plenary session at AANS underscores REYOBIQ’s potential as a differentiated targeted radiotherapeutic platform for CNS cancers <pre>Plenary session at
May 7, 2026
other
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisio
Apr 28, 2026
contract
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers <pre>Expands access by 6 million covere
Apr 23, 2026
other
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
<p align="justify">HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare compan
Apr 22, 2026
other
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- <u>Plus Therapeutics, Inc.</u> (Nasdaq: <u>PSTV</u>) (the “Company”), a healthcare compa
Apr 21, 2026
other
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
<p>HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercia
Apr 15, 2026
other
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting C
Apr 9, 2026
other
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution
Apr 9, 2026
short_interest
FTD: PSTV — 217,227 shares ($0.7M) failed to deliver
Settlement: 20260409, Price: $3.17, FTD Value: $688,609.59, PLUS THERAPEUTICS INC COM PAR
Apr 8, 2026
other
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
<p align="justify">HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=CAqq1nuSSPrOuIhfN2Rm7V4_uk4JmrwWG
Apr 8, 2026
short_interest
FTD: PSTV — 274,728 shares ($0.8M) failed to deliver
Settlement: 20260408, Price: $2.92, FTD Value: $802,205.76, PLUS THERAPEUTICS INC COM PAR